News AbbVie’s Skyrizi hits the spot in refractory psoriasis Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.
News Lilly’s Taltz scrapes win against Humira in psoriatic arthri... Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.
News UK partners with Eli Lilly on obesity plan The UK has teamed up with Eli Lilly on initiatives, backed with £85 million in funding, to expand access to treatment for obesity.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
